Ganciclovir Treatment Contributes to Mutagenesis Post-Transplant

Area of Science:

• Oncology
• Transplantation Medicine
• Genetics

Background:

• Nucleoside analogues are commonly used in post-transplant immunosuppression.
• The long-term effects of these drugs on recipient DNA are not fully understood.
• Understanding treatment-induced genetic alterations is crucial for patient outcomes.

Purpose of the Study:

• To investigate the mutational landscape following nucleoside analogue therapy in transplant recipients.
• To identify novel mutation signatures associated with this treatment.
• To assess the potential of these signatures to drive oncogenesis.

Main Methods:

• Analysis of genomic DNA from transplant recipients treated with nucleoside analogues.
• Whole-genome sequencing to identify mutation patterns.
• Bioinformatic analysis to characterize mutation signatures and assess their functional impact.

Main Results:

• Nucleoside analogue treatment is associated with a distinct and previously unrecognized mutation signature.
• This novel signature exhibits specific patterns of DNA damage and repair.
• The identified mutations show potential oncogenic drivers.

Conclusions:

• Post-transplant nucleoside analogue therapy can induce a unique mutational signature in recipient cells.
• This treatment-associated genomic instability may increase the risk of secondary malignancies.
• Further research is warranted to monitor and mitigate this risk in transplant patients.